2964 related articles for article (PubMed ID: 16691383)
21. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C
Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
[TBL] [Abstract][Full Text] [Related]
22. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
[TBL] [Abstract][Full Text] [Related]
23. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors.
Broekmans FJ; Knauff EA; Valkenburg O; Laven JS; Eijkemans MJ; Fauser BC
BJOG; 2006 Oct; 113(10):1210-7. PubMed ID: 16972863
[TBL] [Abstract][Full Text] [Related]
24. Clinical and biochemical characteristics of polycystic ovary syndrome in Croatian population.
Baldani DP; Skrgatić L; Goldstajn MS; Zlopasa G; Oguić SK; Canić T; Piljek AN
Coll Antropol; 2012 Dec; 36(4):1413-8. PubMed ID: 23390843
[TBL] [Abstract][Full Text] [Related]
25. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism.
Dewailly D; Catteau-Jonard S; Reyss AC; Leroy M; Pigny P
J Clin Endocrinol Metab; 2006 Oct; 91(10):3922-7. PubMed ID: 16849400
[TBL] [Abstract][Full Text] [Related]
26. Low estradiol-to-testosterone ratio is associated with oligo-anovulatory cycles and atherogenic lipidic pattern in women with polycystic ovary syndrome.
Amato MC; Verghi M; Nucera M; Galluzzo A; Giordano C
Gynecol Endocrinol; 2011 Aug; 27(8):579-86. PubMed ID: 20608809
[TBL] [Abstract][Full Text] [Related]
27. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka.
Kumarapeli V; Seneviratne Rde A; Wijeyaratne CN; Yapa RM; Dodampahala SH
Am J Epidemiol; 2008 Aug; 168(3):321-8. PubMed ID: 18550559
[TBL] [Abstract][Full Text] [Related]
28. Is hyperandrogenemia protective for fibrocystic breast disease in PCOS?
Ozkaya E; Cakir E; Cinar M; Kara F; Baser E; Cakir C; Kucukozkan T
Gynecol Endocrinol; 2012 Jun; 28(6):468-71. PubMed ID: 22103710
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic criteria in polycystic ovary syndrome.
Legro RS
Semin Reprod Med; 2003 Aug; 21(3):267-75. PubMed ID: 14593549
[TBL] [Abstract][Full Text] [Related]
30. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women.
Liou TH; Yang JH; Hsieh CH; Lee CY; Hsu CS; Hsu MI
Fertil Steril; 2009 Dec; 92(6):1960-5. PubMed ID: 18980763
[TBL] [Abstract][Full Text] [Related]
31. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
[TBL] [Abstract][Full Text] [Related]
32. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome.
Hart R; Hickey M; Franks S
Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):671-83. PubMed ID: 15380140
[TBL] [Abstract][Full Text] [Related]
33. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Kriplani A; Agarwal N
J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
[TBL] [Abstract][Full Text] [Related]
34. The androgenic profile of women with non-insulin-dependent diabetes mellitus.
Tok EC; Ertunc D; Evruke C; Dilek S
J Reprod Med; 2004 Sep; 49(9):746-52. PubMed ID: 15493567
[TBL] [Abstract][Full Text] [Related]
35. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
[TBL] [Abstract][Full Text] [Related]
36. Plasma selenium levels in Turkish women with polycystic ovary syndrome.
Coskun A; Arikan T; Kilinc M; Arikan DC; Ekerbiçer HÇ
Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):183-6. PubMed ID: 23490536
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of polycystic ovarian syndrome in Indian adolescents.
Nidhi R; Padmalatha V; Nagarathna R; Amritanshu R
J Pediatr Adolesc Gynecol; 2011 Aug; 24(4):223-7. PubMed ID: 21600812
[TBL] [Abstract][Full Text] [Related]
38. Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation.
Sobbrio GA; Granata A; D'Arrigo F; Arena D; Panacea A; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1990; 21(3):139-41. PubMed ID: 2149912
[TBL] [Abstract][Full Text] [Related]
39. Influence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOS.
Cupisti S; Dittrich R; Binder H; Kajaia N; Hoffmann I; Maltaris T; Beckmann MW; Mueller A
Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):380-6. PubMed ID: 17701884
[TBL] [Abstract][Full Text] [Related]
40. The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome.
Hahn S; Fingerhut A; Khomtsiv U; Khomtsiv L; Tan S; Quadbeck B; Herrmann BL; Knebel B; Müller-Wieland D; Mann K; Janssen OE
Clin Endocrinol (Oxf); 2005 May; 62(5):573-9. PubMed ID: 15853827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
